FREE SHIPPING on orders over $150
Track My Order Manage Subscription Sign In Contact Us
Back to 5 MIN READ
AVL Face Cream Rich Clinical Skin Compatibility Evaluation of a Multi-Lipid Face Cream Rich

AVL Face Cream Rich

AVL Face Cream Rich Clinical Skin Compatibility Evaluation of a Multi-Lipid Face Cream Rich

Single-Application Occlusive Patch Test in Sensitive and Normal Skin Cohorts.

Background

Advanced rich cosmetic formulations increasingly combine intensive lipid systems with concentrated active complexes to deliver barrier-support and comfort-oriented skin benefits. Responsible innovation requires that such high-density, multi-component designs be accompanied by rigorous compatibility validation of the finished product.

Objective

To confirm the skin compatibility of a nutrient-rich face cream containing a full spectrum of 21 amino acids, Panthenol (Vitamin B5), and a multi-lipid botanical complex (including shea butter, cupuaçu butter, apple seed oil, and sweet almond oil) using standardized patch-test methodology.

Methods

Two independent monocentric, simple-blind patch test studies were conducted under dermatological supervision at an external clinical investigation center. The product was applied pure (undiluted) under 48-hour occlusion using a standardized Finn Chamber® system. Irritation potential was quantified using the Mean Cumulative Irritation Index (M.C.I.I.).

Results

The face cream demonstrated M.C.I.I. values of 0.03 (sensitive skin cohort, n=54) and 0.00 (normal skin cohort, n=54), both classified as Non-irritating (<0.25).

Conclusion

Despite its formulation richness and multi-lipid complexity, the tested Face Cream Rich exhibited minimal acute irritation potential under high-challenge occlusive conditions, supporting its excellent skin compatibility in both sensitive and normal skin cohorts.

Introduction

Skincare formulas are getting more complex

Modern dermocosmetic formulations increasingly combine multiple active ingredients to enhance performance. However, combining numerous bioactive components - particularly at meaningful concentrations - introduces potential concerns regarding cumulative or synergistic irritation effects.

The scientific question is straightforward
Does increasing formulation complexity proportionally increase irritation risk?

Single-application occlusive patch testing is widely used as a first-line compatibility assessment because it:

  • Standardizes dose, exposure time, and evaluation methodology
  • Creates a controlled high-challenge scenario (48-hour occlusion)
  • Quantifies irritation potential using a validated cumulative index (M.C.I.I.)

This methodology serves as a structured clinical compatibility gate prior to broader consumer-use testing and claim substantiation.

The present publication summarizes two standardized patch test studies of Eye Cream conducted in sensitive and normal skin cohorts.

Materials and methods

Safety Assessment & Application Protocol

Safety Assessment & Application Protocol

Study Design

Type: Single-application occlusive patch test

Design: Monocentric, simple-blind

Supervision: Dermatological control

Setting: Independent external clinical investigation center

Application Protocol

Dose: 20 µL

Product state: Pure (undiluted)

Application system: Occlusive Finn Chamber® (8 mm / 50 mm²)

Exposure duration: 48 hours

Assessment timepoints:

  • 30 minutes post-removal
  • 24 hours post-removal

Outcome Measure

Skin reactions were evaluated according to predefined numerical grading scales for:

  • Erythema (E) — redness

Oedema (O) — swelling

AVL Face Cream Rich

Skin Compatibilty Results

M.C.I.I. provides a quantitative measure of irritation potential under the specific study conditions

Results chart
Cohorts Age Range Phototypes Subjects M.C.I.I Classification
Sensitive Skin 20–70 I–IV 54 0.03 Non-irritating
Normal Skin 20–70 I–IV 55 0.03 Non-irritating

* Interpretation Scale (Max possible value: 6)

Results data
Results data

* Both cohorts independently met the Non-irritating classification threshold (<0.25).

Regulatory and Ethical Compliance

The studies were conducted:

  • Under dermatological supervision
  • In accordance with the Declaration of Helsinki (1964) and subsequent updates
  • Following ICH E6 (R2) Good Clinical Practice principles
  • Within the framework of Regulation (EC) No 1223/2009 on Cosmetic Products
  • In alignment with Commission Regulation (EU) No 655/2013 (cosmetic claims)
  • Under GDPR compliance (Regulation (EU) 2016/679)
  • Within a documented quality management system consistent with internationally recognized standards (e.g., ISO 9001)

Results Discussion

AVL Face Cream Rich formulation integrates a diverse active profile, including a full complement of 21 amino acids and multiple botanical and skin-supportive ingredients. Despite this complexity, the product demonstrated very low cumulative irritation values in both normal and sensitive skin cohorts.

The tested Face Cream Rich integrates:

  • Panthenol (Vitamin B5)
  • Butyrospermum Parkii Butter (shea butter)
  • Tremella Fuciformis Extract
  • Pyrus Malus Seed Oil (apple seed oil)
  • Prunus Amygdalus Dulcis Oil
  • Theobroma Grandiflorum Seed Butter
  • Sambucus Nigra Flower Powder

Rather than assuming compatibility based on ingredient-level safety, the finished formulation was evaluated under controlled, standardized conditions using a 48-hour occlusive patch-test model — a recognized high-challenge scenario for assessing acute irritation potential.

The observed M.C.I.I. values of 0.03 (sensitive skin) and 0.00 (normal skin) fall well below the 0.25 threshold for Non-irritating classification. These results were consistent across two independent cohorts representing.

Tested at Full Strength

PATCH TESTING IS ONE OF THE CLEANEST FIRST ANSWERS BECAUSE IT:

✓ Pure (Undiluted)
✓ Under Occlusion
✓ Uredefined classification thresholds
✓ Using predefined classification thresholds With quantitative scoring methodology

These Findings demonstrate that formulation complexity, when engineered with precision and balance, can coexist with excellent skin compatibility. The study reinforces a core development principle: Performance and gentleness are not opposing goals they are complementary outcomes of disciplined formulation science.

References

  1. European Parliament & Council. (2009). Regulation (EC) No. 1223/2009 on Cosmetic Products, Official Journal of the European Union. This regulation sets out the legal framework for cosmetic safety assessment in the EU, including requirements for demonstrating product safety prior to market placement.
  2. Scientific Committee on Consumer Safety (SCCS). (2021). Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation (11th Revision, SCCS/1628/21). European Commission. Provides scientific guidance on safety evaluation of cosmetics and ingredients under EU law, including considerations on human data for local effects.
  3. Api, A. M., et al. (2021). Draize human repeat insult patch test (HRIPT): Seven decades of protocols and standardization challenges. Toxicology in Vitro. Highlights variability and historical evolution of HRIPT approaches relevant to skin compatibility assessment.